PPBT PRESS-RELEASE SEC Filing Analysis

Final — all horizons settled through T+60d ⚠ clustered

PPBT ▼ -28.78% at T+60d

NEUTRAL call ✗ call lost -28.78% · α vs SPY -40.40% · entry $4.10 → $2.92

Currently $1.58 · -61.46% from $4.10 entry

Entry anchored
Mar 12, 12:52 PM ET
via Databento tick

T+1d

-0.24%

call -0.24% · α -1.27%

$4.09

settled 3mo ago

T+5d

-2.93%

call -2.93% · α -0.81%

$3.98

settled 3mo ago

T+20d

+0.73%

call +0.73% · α -2.86%

$4.13

settled 2mo ago

T+60d

-28.78%

call -28.78% · α -40.40%

$2.92

settled 4d ago

Price Chart

Loading chart...

Executive Summary

Purple Biotech reported a significant net loss of $26.4 million for 2025, driven by a $20.5 million impairment charge related to the discontinuation of CM24 and NT219 programs. However, the company highlighted progress in its CAPTN-3 platform, including preclinical success and a $9.5 million cash position providing runway into 2027. Despite strong R&D advancements, the substantial loss and program discontinuations weigh on near-term fundamentals.

Key Financial Metrics

EPS

$-54.96

Actionable Insight

The stock may react positively to the CAPTN-3 platform's preclinical data and extended cash runway, but traders should monitor for partnership developments on discontinued assets and upcoming clinical trial initiations for IM1240. The lack of revenue and continued losses remain key risks.

Key Facts

Reported net loss of $26.4 million for 2025, up from $7.2 million in 2024, primarily due to a $20.5 million impairment charge on CM24 and NT219 programs
Cash and cash equivalents totaled $9.5 million as of December 31, 2025, expected to fund operations into 2027
Achieved key preclinical milestones for IM1240 and IM1305, including toxicology and manufacturing success, with data showing multi-arm anti-tumor activity
R&D expenses decreased to $3.7 million in 2025 from $7.6 million in 2024 due to reduced clinical trial costs, despite increased CMC activities
Company will not advance CM24 and NT219 without a strategic partner or additional financing

Financial Impact

Impairment charge of $20.5 million significantly increased net loss; R&D spending cut in half year-over-year excluding non-cash items

net lossintangible assetsR&D expensescash runway

Risk Factors

Dependence on future financing or partnerships to advance legacy programs CM24 and NT219
High cash burn relative to market cap; any delay in CAPTN-3 development could pressure liquidity
Preclinical data may not translate into clinical success; no near-term revenue catalysts

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3255440

5 reports for PPBT

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for PPBT — sortable, filterable
	Type				Now
May 15, 2026 29d ago	Press Release NEUTRAL ★ 4/10	$3.94 $2.88	▼ −26.90%	▼ −27.87%	$1.58 (−59.90%)
Apr 27, 2026 6w ago	6-K BULLISH ★ 7/10	$4.59 $4.22	▼ −8.06%	▼ −8.46%	$1.58 (−65.58%)
Apr 23, 2026 7w ago	6-K NEUTRAL ★ 3/10	$4.55 $4.23	▼ −7.03%	▼ −8.51%	$1.58 (−65.27%)
Mar 13, 2026 13w ago	Press Release NEUTRAL ★ 3/10	$4.10 $3.98	▼ −2.93%	▼ −0.81%	$1.58 (−61.46%)
Mar 13, 2026 13w ago	Press Release MIXED ★ 6/10	$4.10 $3.98	▼ −2.93%	▼ −0.81%	$1.58 (−61.46%)

US Market Status

Market Closed — Opens Mon (49h 39m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access